CCDC106 and cervical cancer: Inhibiting CCDC106 phosphorylation by substituting both S130 and S147 with alanine or treating cells with the CK2 inhibitor CX4945 abrogated CCDC106-induced p53 degradation and its oncogenic function in breast and cervical cancer cells.